

REGISTER BY JANUARY 17, 2020 AND SAVE \$300!

PRICING & CONTRACTING SERIES

MEDICARE PRICING & CONTRACTING CONGRESS

The Latest Policies and Reform Initiatives Impacting Pricing, Strategy, Quality and Transparency

FEBRUARY 25-26, 2020 | HILTON ALEXANDRIA OLD TOWN | ALEXANDRIA, VA

Progressive Insights and Practical Strategies from Key Thought-Leaders, Including:



Mike Anderson, Pharm.D.,
CEO, Part D,
**UnitedHealthcare
Medicare & Retirement**



Michelle Drozd,
Executive Director,
Reimbursement Policy,
Gilead



Kendra Martello, Executive
Director, Public Policy and
Corporate Social Responsibility,
Mallinckrodt Pharmaceuticals



Laura Crown, Senior Director,
Government Programs
Market Strategy and Support,
Express Scripts



Steve Phillips, Senior Director,
Health Policy, Worldwide
Government Affairs and
Policy, **Johnson & Johnson**



John Wells, Former Vice
President and Chief Medicare
Compliance Officer,
Aetna



Dan Wygal,
Executive Director, Contract
and Channel Strategy,
AstraZeneca Pharmaceuticals

ADDITIONAL PERSPECTIVES FROM:

AARP Public Policy Institute ★ **American Action Forum** ★ **Association for Accessible Medicines**
Deloitte ★ **Incyte** ★ **Gorman Group** ★ **U.S. Government Accountability Office**
Milliman ★ **Health Policy Strategies** ★ **Nightingale Partners** ★ **NORC at the University
of Chicago** ★ **PhRMA** ★ **And More!**

**NEW FOR
2020!**

CHOOSE BETWEEN TWO TRACKS OF EDUCATION:

**I. Pricing and Contracting
For Manufacturers**

**II. Part D Plan Strategies
For Health Plans and PBMs**



Media Partners:



REGISTER AT WWW.CBINET.COM/MEDICARE2020 ★ 800-817-8601

WHAT TO EXPECT...

Informa Connect-CBI's **Medicare Pricing & Contracting Congress** expands to convene stakeholders representing bio/pharma manufacturers, health plans, PBMs and leading policy advisors to provide critical updates and analysis on the changing Medicare landscape for 2020 and beyond. Join the discussion and gain key takeaways on important issues, including the impact of changing legislation, drug pricing transparency, value-based contracting and updates on the International Pricing Index Model and the Most Favored-Nations Clause.

In-Depth Discussions on High-Impact Issues, Including:

- Political and legislative trends impacting coverage and access
- The finalized CMS rule supporting Medicare coverage for gene therapy
- Changes to Part B and ASP reporting requirements
- Trends and insights into Part D drug spending
- Balancing care and quality while delivering patient-centric outcomes
- Approaches for value-based contracting and alternative payment models

OUR CORE AUDIENCE

Bio/Pharma Manufacturers, PBMs and Health Plans with responsibilities for:



DAY ONE TUESDAY, FEBRUARY 25, 20207:30 *Conference Registration & Networking Breakfast*8:30 *Conference Chair's Welcome & Opening Remarks**Regan Pennypacker,
President,
Ancorat Consulting*8:45 **STATE OF THE INDUSTRY**
**Stay on the Pulse of Policy Trends
Impacting the Healthcare Landscape**

- Examine the current policy landscape and proposals from the Trump Administration
- Discuss proposed reforms to Medicare Parts B and D
- Review outlook for the International Pricing Index model (IPI)

*Craig Burton,
Vice President, Policy,
Association for Accessible Medicines*9:30 **Analyze Initiatives and Legislative
Proposals on Drug Pricing**

- Hear an update on the many proposals from Congress to lower drug prices and analyze of the impact each would have on Medicare
- Learn about efforts various committees have undertaken to handle prescription drug prices
- Dive into the proposal from the Pelosi team and what impact it will have on negotiating drug prices
- Evaluate legislation moving through Congress affecting reimbursement for drugs in Medicare and Medicaid

*Lisa Joldersma,
Senior Vice President, Policy and Research,
PhRMA*10:15 *Networking and Refreshment Break*10:45 **GAO ADDRESS**
**Trends and Insights into Part D
Drug Spending and PBM Utilization
Management**

- Discuss findings from the July 2019 GAO report "Medicare Part D: Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization"
- Examine trends in Part D drug rebates and expenditures, 2014-2016
- Explore information on PBM use and how PBMs earn revenue for the services provided to Part D plan sponsors
- Gain insight into GAO's previous and ongoing work related to drug pricing

*John Dicken, Director,
Health Care, Public Health and Private Markets,
U.S. Government Accountability Office**Robert Copeland,
Assistant Director, Health Care,
U.S. Government Accountability Office*11:30 **A Guide to Healthcare Reform and the
2020 Elections**

- Learn about the healthcare proposals being laid out by the 2020 presidential candidates
- Understand each candidates' position on the future of Medicare
- Hear the debate and gain insight into the future of healthcare, the impact on the industry and the effects on the economy

*Douglas Holtz-Eakin,
President,
American Action Forum*12:15 *Networking Luncheon*1:15 **Proposed Changes to Medicare
Prescription Drug Coverage — Impact on
the Program and Its Beneficiaries**

- Evaluate why prescription drug prices and coverage matter to AARP and its members
- Learn about efforts to improve prescription drug coverage, affordability and access
- Gain insight into proposals to allow Medicare to negotiate drug prices
- Hear about additional proposals to modify Medicare drug coverage, including rethinking the Part D benefit structure

*Leigh Purvis,
Director, Health Services Research,
AARP Public Policy Institute*2:00 **PHYSICIAN ADDRESS**
**Evaluate Reimbursement and
Value-Based Payment Initiatives**

- Benefit from hearing recent Medicare reform proposals, including proposed rules on physician payment policies
- Analyze proposed changes to reimbursement rates for certain procedures and treatments
- Understand the impact of new proposed changes on value-based payment initiatives

*Gayle Lee, J.D.,
Director, Physician Payment Policy and Quality,
Association of American Medical Colleges*2:45 *Networking and Refreshment Break*

3:15 CHOOSE BETWEEN TWO TOPIC INTENSIVES (A-B)

A Pull Back the Curtain — Tactics and Strategies for Bid Development

- Learn how pharma bids impact formulary placement, Medicare plan premiums and overall plan strategies
- Illuminate the impact of potential Part D program reforms and learn why these not-yet-enacted reforms may already be impacting plan strategies and pharma negotiations
- Understand the tools and analyses used by actuaries so you can tailor your message to resonate with the people behind the scenes



David Mike, FSA, MAAA,
Consulting Actuary,
Milliman

B Restructure and Reform of Part D Impacts to Health Plans and PBMs

- Break down the Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and other Congressional Proposals
- Explore the different Part D reform proposals and both intended and unintended impacts
- Assess the effects these changes may have on the federal government and patient's out-of-pocket costs, premiums and access



Mike Anderson, Pharm.D.,
CEO, Part D,
UnitedHealthcare Medicare & Retirement

4:00 Session Transition

4:10 CHOOSE BETWEEN TWO TOPIC INTENSIVES (C-D)

C Manufacturer Think Tank — Examine Changes to Part D and Industry Impacts

- Review the effects to budgets and Medicare program spending
- Explore each of the changes and what the intended and unintended impacts could be on the various stakeholders
- Assess the effects these proposals have on beneficiaries' drug costs, premiums and access to medication

FACILITATORS:



Michelle Drozd,
Executive Director, Reimbursement Policy,,
Gilead



Mallory O'Connor,
Director, Public Policy,
Mallinckrodt Pharmaceuticals



Laurel Todd,
Vice President, Government Affairs and Policy,
Incyte

D Address What's Next for the Star Ratings System in Medicare Advantage

- Harness data analytics to recognize opportunities and improve outcomes for all stakeholders
- Identify innovative opportunities to reduce cost of care for patients



Melissa Smith,
Senior Vice President, Stars & Strategy
Gorman Health Group

5:00 Close of Day One



NETWORKING, WINE AND CHEESE RECEPTION

immediately following the final session on day one

DAY TWO WEDNESDAY, FEBRUARY 26, 2020

7:45 *Networking Breakfast*

8:15 CHOOSE BETWEEN TWO TRACKS OF CONTENT (I-II)

Track I

PRICING & CONTRACTING *For Manufacturers*

8:15 *Track Chair's Welcome*



*Mallory O'Connor,
Director, Public Policy,
Mallinckrodt Pharmaceuticals*

8:30 **Assess the Impact of International Price Benchmarks**

- Gain insight into what changes have been made to the IPI model from the advanced rule to the proposed rule
- Learn what the U.S. government's approach has been regarding trade protection vs. price control
- Determine what the operational changes, pitfalls and opportunities will be if IPI is finalized



*Steve Phillips, Senior Director,
Health Policy Worldwide Government Affairs and Policy,
Johnson & Johnson*

9:15 **Delve Into the Latest in Step Therapy**

- Gain insights into data surrounding step therapy in Part B
- Consider how step therapy may influence Part B drug pricing
- Discuss the Administration's recent rule to allow cross-program step therapy, which allows Part D drugs to be required as first step before a Part B drug or vice versa



*Mallory O'Connor,
Director, Public Policy,
Mallinckrodt Pharmaceuticals*

10:00 *Networking and Refreshment Break*

Track II

PART D PLAN STRATEGIES *For Payers and PBMs*

8:15 *Track Chair's Welcome*



*John Wells, Independent Consultant; Former
Vice President and Chief Medicare Compliance Officer,
Aetna*

8:30 **Preparing for the 2021 Medicare Advantage and Part D Landscape**

- Explore the importance of combined Part C/D strategy to address changes in MA requirements and Part D coverage
- Discuss enrollment of individuals with ESRD
- Assess MA Hospice Carve-in Demonstration
- Review recent trends in Part C requirements and prescription drug pricing and coverage/formulary design



*Narda Ipakchi,
Senior Consultant,
Health Management Associates*

9:15 **Future of Drug Pricing — Taking a Medicare Lens**

- Opportunities and challenges the current regulatory landscape has had on Medicare Part D
- Discuss value and outcomes-based contracting with drug manufacturers in regulated markets
- Delve into how PBMs partner and help coordinate the patient journey with health plans



*Laura Crown, Senior Director,
Government Programs Market Strategy and Support,
Express Scripts*

10:00 *Networking and Refreshment Break*

10:30 **Trends in Medicare Advantage and Part D**

- Highlight where these two programs are heading in 2021 and beyond
- Competitive Landscape — What does it mean for Medicare Advantage and PDP?
- Benefit and cost design trends for Medicare Advantage and PDP

Track I

PRICING & CONTRACTING
For Manufacturers

10:30 **Value-Based Contracting and Outcomes-Based Arrangements as a Driver for Quality and Innovation**

- Hear ways to operationalize a value-based contract within Medicare
- Understand innovative value-based contracts various stakeholders are engaging in
- Assess the impact these frameworks have on patients and their access to medications



Dan Wygal,
Executive Director, Contract and Channel Strategy,
AstraZeneca Pharmaceuticals

11:15 *Track 1 Concludes*

12:00 *Networking Luncheon*

1:00 **Alternative Payment Models — What's New, What's Changing and Are These Programs Working?**

- Understand the landscape of Medicare, Medicaid, Medicare Advantage and commercial alternative payment models (APMs), and what these mean for stakeholders, including health systems, health plans, physicians, life sciences companies and consumers
- Explore in-depth, newer models and those that have been proposed but not adopted
- Review evidence to date on the impact of these models from multiple stakeholder perspectives
- Share insights on what this activity has meant for the industry so far, and scenarios for the future



Sarah Thomas,
Managing Director, Center for Health Solutions,
Deloitte LLP

Track II

PART D PLAN STRATEGIES
For Payers and PBMs

- Will the battleground for membership be Medicare Advantage, PDP or both?
- Will social determinant benefits be essential for membership growth?



John Wells, Independent Consultant; Former Vice President and Chief Medicare Compliance Officer,
Aetna



Regan Pennypacker,
President,
Ancorat Consulting



Scott Ptacek,
Advisor and Consultant

11:15 **Social Determinants of Health Arms Race in Medicare Advantage**

- Discuss the business case for bold anti-poverty initiatives by MA plans and capitated providers
- Explore how market leaders are approaching SDOH supplemental benefits and what to expect
- Evaluate innovative and sustainable financing vehicles for SDOH initiatives



John Gorman,
Founder and Chairman,
Nightingale Partners

1:45 **Forecasting the Future — Vision for Long-Term Medicare and Health System Evolution**

- Discuss the potential impact of the 2020 presidential election on the evolution of the health system
- Anticipate the future of the Medicare system
- Investigate the changing roles of health plans and providers and the impact on patients
- Evaluate key trends impacting the healthcare industry over the next five years



Caroline Pearson,
Senior Vice President,
NORC at the University of Chicago

2:30 *Conference Concludes*

In the News:

“Prescription drug price controls are gaining momentum nationally and also at the state level. Nationally, lowering drug prices using government levers is an area in which there appears to be at least some degree of bipartisan agreement.” — *Forbes, October 2019*

“In the absence of a change in law, Medicare Part D enrollees can expect to face an increase in their out-of-pocket drug costs in 2020. Costs for Part D plan sponsors and drug manufacturers will also increase in dollar terms — but in terms of the share of total drug costs up to the catastrophic threshold, Part D plan sponsors will pay a smaller share in 2020 than in 2019, while manufacturers will pay a larger share. These changes are also likely to affect Part D premiums in 2020 and future years.” — *KFF, October 2019*

“Sen. Elizabeth Warren, the self-professed “I have a plan” candidate, finally has a plan to pay for “Medicare for All.” And within that \$20 trillion proposal lies what drug pricing wonks have long awaited: a plan to address the cost of prescription drugs. She’s making bold promises, too: 70% price reductions for branded drugs under Medicare, and 30% for generics. Under Warren’s plan, prescription drug reform alone is estimated to save taxpayers \$1.7 trillion in the next decade.” — *Stat News, November 2019*

Your Next Opportunity:



6th Edition Drug Pricing Transparency Congress

March 30-31, 2020 • Philadelphia, PA



Medicaid and Government Pricing Congress 2020

May 19-21, 2020 • Orlando, FL



5th Annual IDN and Bio/Pharma Partnering Summit

April 1-3, 2020 • Philadelphia, PA



16th Annual Commercial Contract & Chargeback Excellence

June 23-25, 2020 • Philadelphia, PA



Medicaid Managed Care Congress

May 19-21, 2020 • Orlando, FL



Medicaid Drug Rebate Program

September 15-17, 2020 • Chicago, IL

Reach Out to the Medicare Congress Team to Get Involved:

PROGRAM DEVELOPMENT:



Elise Guerin Saas
elise.guerin@informa.com
 339-298-2251

SPONSORSHIP OPPORTUNITIES:



Karen Hanover
karen.hanover@informa.com
 617-290-6113

REGISTRATION & TEAMS:



Matt Douglas
matthew.douglas@informa.com
 339-298-2144

A GREAT PLACE TO MEET YOUR MARKET!

Maximize your access to decision-makers and align your brand with the life sciences industry’s premier thought-leaders and industry innovators. Informa Connect-CBI’s custom sponsorship programs are designed to support your organization’s overall business development and marketing initiatives through meaningful prospect and customer interactions, brand assertion campaigns and content-rich thought-leadership opportunities. Capitalize on the life sciences community’s premier platform for peer-to-peer exchange, solution driven content and first-in-class networking opportunities. For more information on how to position your company as a sponsor or exhibitor, contact **Karen Hanover** at **617-290-6113** or email **karen.hanover@informa.com**.

REGISTER BY JANUARY 17, 2020 AND SAVE \$300!

MEDICARE PRICING & CONTRACTING CONGRESS

The Latest Policies and Reform Initiatives Impacting Pricing, Strategy, Quality and Transparency

FEBRUARY 25-26, 2020 | HILTON ALEXANDRIA OLD TOWN | ALEXANDRIA, VA



SCAN HERE



4 WAYS TO REGISTER NOW!



WEB
www.cbinet.com/medicare2020



EMAIL
cbireg@cbinet.com



PHONE
800-817-8601
339-298-2100 outside the U.S.



LIVE CHAT
www.cbinet.com/medicare2020



informa connect

Informa Connect-CBI
70 Blanchard Road
Burlington, MA 01803

ANY QUESTIONS OR TO REGISTER CONTACT:



Matt Douglas

PHONE 339-298-2144

EMAIL matthew.douglas@informa.com

Medicare Pricing & Contracting Congress

PC20475

REGISTRATION FEE:

	ADVANTAGE PRICING	Standard	Onsite
Bio/Pharma Manufacturers	\$2099	\$2399	\$2499
Health Plans/PBMs	\$1299	\$1599	\$1699

Register by January 17, 2020 and SAVE \$300. Fee includes continental breakfast, lunch, wine and cheese reception, refreshments and conference documentation. Credit Card (Visa, MC, AMEX, Discover) or checks accepted. Please make checks (in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.) PLEASE NOTE: All advertised discounts are taken from the full, Standard Rate.

GROUP RATE:

Looking to bring your team? Contact Information Services to learn about potential group savings. Call 800-817-8601 or email cbireg@cbinet.com.

** Advantage pricing rates do apply when applicable. Offer may not be combined with any other special pricing promotions. Offer may be used at Informa Connect-CBI co-located events.*

SATISFACTION GUARANTEED:

Informa Connect-CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference, a credit will be awarded towards a comparable Informa Connect-CBI conference of your choice. Please contact 800-817-8601 for further information. Advanced preparation for Informa Connect-CBI conferences is not required.

SUBSTITUTION AND CANCELLATION:

Your registration may be transferred to a member of your organization up to 24 hours in advance of the conference. All cancellations received in writing on or before 14 days prior to the start date of the event will be refunded, less a \$499 administrative charge. No refunds will be made after this date; however, the registration fee less the applicable administrative charge can be credited to another Informa Connect-CBI conference if you register within 30 days from the date of this conference to an alternative Informa Connect-CBI conference scheduled within the next six months. In case of conference cancellation, Informa Connect-CBI's liability is limited to refund of the conference registration fee only. Cancellation of a conference due to events beyond our control* are subject to a \$499 administrative charge, should you or a colleague be unable to attend the rescheduled date. Informa Connect reserves the right to alter this program without prior notice. **Please Note:** Speakers and agenda are subject to change. In the event of a speaker cancellation, every effort to find a suitable replacement will be made. The opinions of the conference faculty do not necessarily reflect those of the companies they represent or Informa Connect-CBI.

*Events beyond our control include: severe weather conditions, natural and man-made disasters and any other similar events.

VENUE:

Hilton Alexandria Old Town

1767 King St

Alexandria, VA 22314

Hotel Direct Line: +1 (703) 837 0440

ACCOMMODATIONS:

To receive Informa Connect-CBI's special discounted hotel rate online, please go to: www.cbinet.com/medicare2020

Book Now! For hotel room availability and direct booking links, please visit www.cbinet.com/medicare2020 and select the Venue-Pricing tab. Rooms are limited so please book early. All travel arrangements are subject to availability.

PLEASE NOTE: All hotel reservations for this conference should be booked directly with the hotel. Informa Connect-CBI does not use Housing Bureaus and none are authorized to call on our behalf.



REGISTER AT WWW.CBINET.COM/MEDICARE2020



800-817-8601